Fill-finish and aseptic manufacturing in Singapore

Runs a roughly 24,000 m2 sterile fill-finish CDMO site at 31 Joo Koon Circle (with reserved expansion of a further ~14,000 m2), offering a high-speed, fully automated aseptic liquid-vial filling line with single-use formulation up to 1,000 litres for both small- and large-molecule products, and reserved future capacity for lyophilised vials, prefilled syringes and cartridges.

A 72-acre multi-product Tuas hub whose chemical plant has historically produced small-molecule APIs (including etoricoxib and simvastatin), with a US$500 million programme adding sterile fill-finish and secondary packaging for biologic products — KEYTRUDA (pembrolizumab) vials and GARDASIL 9 syringes. Singapore headcount exceeds 1,800.

A roughly US$590-638 million modular, digitally-enabled vaccine-and-biologics plant at Tuas designed to switch rapidly between up to four vaccines across protein and mRNA platforms — Sanofi's first fully modular vaccine and biologics site in Asia, engineered for pandemic and regional demand, with captive multi-vaccine drug-product filling built in.

Building a roughly US$1.4 billion integrated CRDMO on a 13.5-hectare Tuas site adding 120,000 litres of biologics capacity and about 1,500 jobs, offering end-to-end drug-substance and drug-product (fill-finish) services across monoclonal antibodies, bispecifics and recombinant proteins on single-use technology.

Building a ~22,000 m2 Tuas facility for ADC and bioconjugate drug substance up to 2,000 litres plus drug-product lyophilisation engineered for over 8 million vials a year, with onsite MSAT and QC.

A roughly US$20 million, ~30,000 sq ft multi-modality vaccine-and-biologics development-and-manufacturing facility at Depot Road (the ACES facility) with end-to-end drug-substance, drug-product and clinical-material capability in isolated single-use suites, focused on mRNA and viral-vector platforms through Phase II; billed as Singapore's only multi-modality vaccine-and-biologics development-and-manufacturing organisation.

A homegrown Singapore CDMO at Ayer Rajah Crescent offering biologics, viral-vector production, cell-therapy manufacturing on its proprietary Tide Motion bioreactor platform, plasmid-DNA manufacturing and small-batch aseptic fill-finish — positioned as Southeast Asia's first small-batch aseptic fill-and-finish service — with an A*STAR bioprocessing partnership.

A large mammalian cell-culture CDMO campus at Tuas producing monoclonal antibodies and recombinant and fusion proteins across 20,000-litre stainless-steel and 2,000-litre single-use suites, with cell-line construction through commercial process validation, purification, viral clearance and fill, plus an allogeneic cell-therapy centre of excellence and a strong regulatory-inspection record.